Comprehensive overview of consumer (patient) posts from June 2014-September 2016 from key websites.

Please note: Although the competitive set of products for the report is set based on Rheumatoid Arthritis, the searches include product reviews for inflammatory conditions other than RA (e.g., OA, PsA). This is because on-line searchers are likely to see and read on-line posts from patients and potential users who potentially could have conditions other than RA.

Posts cover the following treatments:

  • Actemra
  • Arava
  • Arthrotec
  • Cimzia
  • Enbrel
  • Humira
  • Kineret
  • Methotrexate
  • Orencia
  • Remicade
  • Rituxan
  • Simponi
  • Vimovo
  • Xeljanz

Report explains the following:

  • Sentiment toward individual treatments
  • Patient characteristics associated with each treatment
  • Clinical outcomes, side effects, and other comparisons for each treatment
  • Treatment dynamics associated with obtaining and taking therapies
  • Treatment dynamics changes from June 2014 to September 2016

Refer to the Hepatitis C report to obtain a free sample (~10 slides) of types of data available in the report.